Dr Hoda Abdel-Aty

Dr Hoda Abdel-Aty is a highly accomplished Consultant Clinical Oncologist who specialises in the treatment and management of prostate cancer. With a deep commitment to patient-centred care, she focuses on delivering advanced, evidence-based oncological treatments. Her clinical expertise spans technical radiotherapy, radioligand therapy, and molecular imaging, ensuring that patients receive highly precise and tailored therapeutic interventions.

In addition to her clinical practice, Dr Abdel-Aty is actively involved in pioneering clinical research aimed at improving patient outcomes. She co-leads major clinical trials, including comparisons involving stereotactic ablative radiotherapy (SABR) and 177Lutetium-PSMA-617. Her contributions to the field include developing national radiotherapy guidelines and collaborating closely with quality assurance groups. She has also championed the integration of artificial intelligence in molecular imaging, introducing advanced reporting platforms to support quantitative analysis and enhance diagnostic precision.

Dr Abdel-Aty completed her medical degree (MBChB) and subsequently earned a Master of Science (MSc) in Oncology with Merit. She was awarded a Doctor of Medicine (Research) degree, with her doctoral research focusing on the impact of next-generation imaging on staging and treatment selection in advanced prostate cancer. She is a Member of the Royal College of Physicians (MRCP) and a Fellow of the Royal College of Radiologists (FRCR). Committed to education, she also serves as a Module Lead for postgraduate oncology programmes, training the next generation of clinicians and researchers.